Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells

被引:78
作者
Xu, Q
Takekida, S
Ohara, N
Chen, W
Sitruk-Ware, R
Johansson, EDB
Maruo, T
机构
[1] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Populat Council, Ctr Biomed Res, New York, NY 10021 USA
关键词
D O I
10.1210/jc.2004-1569
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study was conducted to evaluate the effects of the progesterone receptor modulator CDB-2914 on proliferative activity and apoptosis in cultured human uterine leiomyoma cells. Isolated leiomyoma cells were subcultured in phenol red-free DMEM supplemented with 10% fetal bovine serum for 120 h and then stepped down to serum-free conditions for 12, 24, 48, and 96 h in the absence or presence of graded concentrations of CDB-2914 (10(-9), 10(-8), 10(-7), and 10(-6) M). The number of viable cultured leiomyoma cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazodium bromide assay. Proliferating cell nuclear antigen (PCNA) expression was evaluated by immunocytochemistry and Western blot analysis. Apoptosis was examined by terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling (TUNEL) assay. Caspase-3, cleaved poly(ADPribose) polymerase (PARP), and Bcl-2 expression were assessed by Western blot analysis. Compared with untreated control cultures, treatment with CDB-2914 decreased the number of viable cultured leiomyoma cells and the PCNA-positive rate in those cells and increased the TUNEL-positive rate in cultured leiomyoma cells in a dose-dependent manner. Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures. These results suggest that CDB-2914 inhibits the proliferation of cultured leiomyoma cells by down-regulating PCNA expression and induces apoptosis by up-regulating cleaved caspase-3 and PARP expression and down-regulating Bcl-2 protein expression in those cells.
引用
收藏
页码:953 / 961
页数:9
相关论文
共 55 条
[1]   CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914 [J].
Attardi, BJ ;
Burgenson, J ;
Hild, SA ;
Reel, JR ;
Blye, RP .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 188 (1-2) :111-123
[2]   Development of the selective progesterone receptor modulator CDB-2914 for clinical indications [J].
Blithe, DL ;
Nieman, LK ;
Blye, RP ;
Stratton, P ;
Passaro, M .
STEROIDS, 2003, 68 (10-13) :1013-1017
[3]   Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis - Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells [J].
Boulares, AH ;
Yakovlev, AG ;
Ivanova, V ;
Stoica, BA ;
Wang, GP ;
Iyer, S ;
Smulson, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) :22932-22940
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-β expression [J].
Chegini, N ;
Ma, C ;
Tang, XM ;
Williams, RS .
MOLECULAR HUMAN REPRODUCTION, 2002, 8 (12) :1071-1078
[6]   Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium [J].
Chwalisz, K ;
Brenner, RM ;
Fuhrmann, UU ;
Hess-Stumpp, H ;
Elger, W .
STEROIDS, 2000, 65 (10-11) :741-751
[7]   Caspases: the executioners of apoptosis [J].
Cohen, GM .
BIOCHEMICAL JOURNAL, 1997, 326 :1-16
[8]  
D'Amours D, 2001, J CELL SCI, V114, P3771
[9]   Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen [J].
Darro, F ;
Cahen, P ;
Vianna, A ;
Decaestecker, C ;
Nogaret, JM ;
Leblond, B ;
Chaboteaux, C ;
Ramos, C ;
Pétein, M ;
Budel, V ;
Schoofs, A ;
Pourrias, B ;
Kiss, R .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (01) :39-55
[10]  
Eid MA, 2002, MOL CANCER THER, V1, P831